Antibiotic drugs

Boulos & Cooper Pharmaceuticals priority antibiotic programs have been selected by the board of Directors for priority development based on the prevalence of the disease targets, the resistance to existing antibiotic treatments for these diseases and speed and cost-to-market considerations.

In the US alone, each of the medical conditions mentioned above affects at least 250,000 people per year and their combined economic effect is approximately US$40 billion annually. Moreover, due to the high levels of resistance to existing antibiotic treatments and few treatment options, CDI, Gonorrhoea and some Gram-negative bacteria are the three bacteria classified as “urgent-level” by the US Department of Health and Human Services’ Centers for Disease Control and Prevention (“CDC”) – its highest category of threat level – declaring each of them “an immediate public health threat that requires urgent and aggressive attention”.

 

Learn more